A class action lawsuit has been filed against Bloom Energy Corporation alleging the company failed to disclose its reliance on scandium sourced indirectly from China. The complaint claims Bloom Energy understated its dependence on Chinese scandium, making its positive business statements misleading. The issue came to light after a report revealed multiple China-linked supply routes for scandium used by Bloom. Following the report, Bloom's stock price dropped 5.7% on heavy trading. Investors who bought shares between February 2025 and July 2026 are encouraged to consider legal action before the September 28, 2026 deadline.
Anthropic reported a massive increase in revenue, reaching $16.3 billion in the first half of 2026 compared to just $1.1 billion in the same period last year. This surge highlights rapid growth and strong demand for its products or services. The dram...
Early Ethereum investors sold a total of 4,000 ETH from two wallets, with one ICO participant selling 1,000 ETH and another holder offloading 3,000 ETH worth $7.23 million. This activity coincides with Santiment's report of the largest daily net ETH ...
Immatics presented encouraging clinical data for its IMA402 PRAME bispecific and IMA203CD8 PRAME cell therapies at the 2026 ESMO Annual Meeting. IMA402 showed a 32% confirmed objective response rate (cORR) in advanced melanoma patients with high PRAM...
Eli Lilly's investigational drug sofetabart mipitecan (Sofe-M), combined with bevacizumab, achieved a 79% confirmed objective response rate and 100% disease control rate in a Phase 1 study involving platinum-sensitive ovarian cancer patients. The tre...
Zymeworks presented new Phase 1 data for ZW191, an antibody-drug conjugate targeting folate receptor alpha, showing a 64.5% confirmed response rate at the 6.4 mg/kg dose in heavily pretreated patients with platinum-resistant ovarian cancer. The treat...
